NYMC Faculty Publications
Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
Author Type(s)
Faculty
DOI
10.1097/CRD.0000000000000452
Journal Title
Cardiology in Review
First Page
214
Last Page
219
Document Type
Article
Publication Date
7-1-2022
Department
Medicine
Abstract
Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation.
Recommended Citation
Hughes-Hubley, F., Iskander, M., Cheng-Lai, A., Frishman, W. H., & Nawarskas, J. (2022). Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia. Cardiology in Review, 30 (4), 214-219. https://doi.org/10.1097/CRD.0000000000000452